The DOI matches its Crossref record; 608 of the 608 references it cites were found in a registry or an index.
Cancer prevention and therapy through the modulation of the tumor microenvironment
Open accessAbstract
Cancer arises in the context of an in vivo tumor microenvironment. This microenvironment is both a cause and consequence of tumorigenesis. Tumor and host cells co-evolve dynamically through indirect and direct cellular interactions, eliciting multiscale effects on many biological programs, including cellular proliferation, growth, and metabolism, as well as angiogenesis and hypoxia and innate and adaptive immunity. Here we highlight specific biological processes that could be exploited as targets for the prevention and therapy of cancer. Specifically, we describe how inhibition of targets such as cholesterol synthesis and metabolites, reactive oxygen species and hypoxia, macrophage activation and conversion, indoleamine 2,3-dioxygenase regulation of dendritic cells, vascular endothelial growth factor regulation of angiogenesis, fibrosis inhibition, endoglin, and Janus kinase signaling emerge as examples of important potential nexuses in the regulation of tumorigenesis and the tumor microenvironment that can be targeted. We have also identified therapeutic agents as approaches, in particular natural products such as berberine, resveratrol, onionin A, epigallocatechin gallate, genistein, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone, that may warrant further investigation to target the tumor microenvironment for the treatment and/or prevention of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
Ji, Q., Liu, X., Fu, X., Zhang, L., Sui, H., Zhou, L., Sun, J., Cai, J., Qin, J., Ren, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078700 · Cited by 354
RetractedMantena, S. K., Sharma, S. D., & Katiyar, S. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl043 · Cited by 174
RetractedWang, Z. P., Zhang, Y., Banerjee, S., Li, Y., & Sarkar, F. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21589 · Cited by 123
RetractedRETRACTED: Redox Regulation of the AMP-Activated Protein Kinase
Han, Y., Wang, Q., Song, P., Zhu, Y., & Zou, M.-H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015420 · Cited by 71
RetractedCurcumin inhibits lung cancer progression and metastasis through induction of FOXO1
Li, Z.-C., Zhang, L., Wang, H., Ma, J., & Sun, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1013-7 · Cited by 42
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citation
Cited by
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening
Ferreira, L. P., Gaspar, V. M., Mendes, L., Duarte, I. F., & Mano, J. F. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120983 · Cited by 59
Erazo-Oliveras, A., Muñoz-Vega, M., Mlih, M., Thiriveedi, V., Salinas, M. L., Rivera-Rodríguez, J. M., Kim, E., Wright, R. C., Wang, X., Landrock, K. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39640-w · Cited by 27
Metadata
- Authors
- Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., Crawford, S., Fujii, H., Georgakilas, A. G., Guha, G., Halicka, D., Helferich, W. G., Heneberg, P., Honoki, K., Keith, W. N., Kerkar, S. P., Mohammed, S. I., Niccolai, E., Nowsheen, S., Vasantha Rupasinghe, H. P., Samadi, A., Singh, N., Talib, W. H., Venkateswaran, V., Whelan, R. L., Yang, X., & Felsher, D. W.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 35
- Pages
- S199-S223
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2012576981
- Cited by
- 372
- References
- 608
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer prevention and therapy through the modulation of the tumor microenvironment. https://app.cochat.ai/papers/10.1016/j.semcancer.2015.02.007
- The paper
- Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., Crawford, S., Fujii, H., Georgakilas, A. G., Guha, G., Halicka, D., Helferich, W. G., Heneberg, P., Honoki, K., Keith, W. N., . . . Felsher, D. W. (2015). Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2015.02.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.